ArticleScientific reports2025
Environmental exposure to perfluorooctane sulfonate and its role in esophageal cancer progression: a comprehensive bioinformatics and experimental study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bisphenol A promotes esophageal carcinogenesis by activating the MMP1-PCOLCE regulatory axis and remodeling the tumor immune microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (ESCA) is a significant malignancy with rising global incidence rates and considerable impacts on patient survival and quality of life. Current diagnostic and therapeutic strategies face limitations, necessitating research into its underlying mechanisms and potential biomarkers for early diagnosis. This study aims to investigate the role of perfluorooctane sulfonate (PFOS), an environmental toxicant, in the development of ESCA through a comprehensive bioinformatics approach. Using the TCGA-ESCA dataset, we identified differentially expressed genes (DEGs) and intersected them with PFOS-related toxicity targets predicted via Comparative Toxicogenomics Database (CTD) and SuperPred. Machine learning (Random Forest, XGBoost, LASSO, SVM) were applied to prioritize core targets. Survival analysis, in vitro qPCR (ESO-26/FLO-1 cells), and molecular docking were performed. Immune infiltration and pathway activity (GSVA) were assessed. We identified 98 PFOS-related DEGs in ESCA, enriched in hypoxia response, epithelial migration, and cancer-associated pathways (e.g., AGE-RAGE, PI3K-Akt). Machine learning highlighted three core targets: PLAU, TOP2A, and BAX. High expression of these genes correlated with poor survival (PLAU, p = 0.047) and was upregulated in ESCA tissues. PFOS exposure significantly elevated their expression in esophageal cancer cells. Molecular docking revealed strong binding affinities between PFOS and core targets. GSVA linked PLAU/TOP2A/BAX to oncogenic pathways (angiogenesis, DNA repair), while immune analysis showed PLAU's association with stromal infiltration and TOP2A's negative correlation with CD8 + T cells. PFOS exacerbates ESCA by dysregulating PLAU, TOP2A, and BAX, which drive tumor progression via immune modulation, genomic instability, and oncogenic signaling. These targets may serve as biomarkers and therapeutic vulnerabilities for PFOS-associated ESCA, underscoring the need for environmental regulation and targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.